Telomium
Ivry-sur-seine
About Telomium
Telomium is a biotechnology company developing a cancer immunotherapy product with a unique composition in the present pharmacopoeia: a ribonucleoprotein, which has the ability to mimic a viral attack and induce an auto-immune reaction targeted against any form of cancer, without causing significant side effects. This self-vectored and self-adjuvanted vaccine is based on the telomerase ribonucleoprotein particle prepared from a patented, safe and competitive yeast-based technology using a breakthrough innovation in the production of the recombinant telomerase protein.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Last round: Series Unknown (Jun 2016)
- Website: telomium.com
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/telomium-3351778 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.